[go: up one dir, main page]

Warden-Rothman, 2015 - Google Patents

The development, use, and optimization of sortase-tag expressed protein ligation

Warden-Rothman, 2015

View PDF
Document ID
964318357098200554
Author
Warden-Rothman R
Publication year

External Links

Snippet

Molecular imaging is an emerging field that seeks to combine the mechanistic detail of biochemical assays with the the broad phenotypic data obtained from non-invasive medical imaging. A cornerstone of molecular imaging is the ability to chemically attach a contrast …
Continue reading at core.ac.uk (PDF) (other versions)

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1037Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48853Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
    • A61K47/48861Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being an inorganic particle, e.g. a ceramic particle, silica particle, ferrite, synsorb
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48369Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations

Similar Documents

Publication Publication Date Title
Sioud Phage display libraries: from binders to targeted drug delivery and human therapeutics
Löfblom et al. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications
Ståhl et al. Affibody molecules in biotechnological and medical applications
Heo et al. An aptamer-antibody complex (oligobody) as a novel delivery platform for targeted cancer therapies
US10156559B2 (en) Lipocalin fusion partners
Miller et al. T cell receptor-like recognition of tumor in vivo by synthetic antibody fragment
US10738115B2 (en) Humanized antibodies transmigrating the blood-brain barrier and uses thereof
Sánchez-Martín et al. The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies
US20170267755A1 (en) Isolated anti-mesothelin antibodies, conjugates and uses thereof
CN114106099A (en) Substrates and other cleavable moieties for proteolytic enzymes and U-type plasminogen activators and methods of use thereof
US10605810B2 (en) Pincers comprising antibody and aptamer conjugated via a linker which binds to the same target material and use thereof
JP2014515600A5 (en)
Pung et al. Generation of peptides using phage display technology for cancer diagnosis and molecular imaging
CN116444666A (en) Preparation method and application of CDH17 specific diagnosis and treatment integrated molecular imaging probe
CN115461354B (en) Tandem repeat cancer targeting peptides for molecular conjugation or modification and their use in cancer theranostics
Choi et al. Complexation of drug and hapten-conjugated aptamer with universal hapten antibody for pancreatic cancer treatment
WO2022148491A1 (en) Assembled protein element and use thereof
JP6969014B2 (en) How to bond antibody and bioactive substance
CN115925951A (en) Preparation method and application of CD70 specific diagnosis and treatment integrated molecular image probe
US8507207B2 (en) Recombinant nucleotide sequence, cell or vector containing the same and method for using cell containing the same to encode anti-polyethylene glycol monoclonal antibodies
Pozdniakova et al. Using ELP repeats as a scaffold for de novo construction of gadolinium-binding domains within multifunctional recombinant proteins for targeted delivery of gadolinium to tumour cells
Case et al. Engineered charge redistribution of Gp2 proteins through guided diversity for improved PET imaging of epidermal growth factor receptor
Case et al. Evaluation of affibody charge modification identified by synthetic consensus design in molecular PET imaging of epidermal growth factor receptor
Warden-Rothman The development, use, and optimization of sortase-tag expressed protein ligation
oh Jung et al. A new fluorescence/PET probe for targeting intracellular human telomerase reverse transcriptase (hTERT) using Tat peptide-conjugated IgM